"4CB is an example of integration between healthcare, research and teaching, and these contributions to ESMO demonstrate how translational and clinical research can transform medical practice and generate real impact in society," highlights Elias Campo, Director of Research at 4CB.
Prominent presence in oral sessions and international studies
Of the total contributions, 16 were oral, educational or leadership presentations, while 36 were posters or ePosters. 4CB participated in high-impact international clinical trials, including phase III studies and late-breaking abstract presentations.
Breast and lung cancer: main research areas
The most represented areas were breast cancer and lung cancer, with eight studies each. In both fields, advances were presented in innovative therapeutic strategies, immunotherapy and studies in specific populations.
Transversal research in other tumor types
Relevant studies were also presented in liver and biliary tract cancer (5); upper digestive tumors —pancreas, stomach or esophagus— (5); colorectal cancer (2); gynecological and bladder cancer (7); urological tumors, prostate and kidney (6); melanoma and other skin tumors (3); and brain tumors (1).
Additionally, contributions were made in transversal areas such as translational immunotherapy, supportive cancer care, toxicities and thrombosis.
Scientific and educational leadership
Researchers from Clínic-IDIBAPS also had a prominent presence as speakers and moderators in educational and discussion sessions, reaffirming their scientific and educational leadership within the international oncology community.
"This level of participation at ESMO reflects the scientific and clinical potential of our center, but above all the talent and collaboration of hundreds of professionals committed to improving the lives of people with cancer," concludes Aleix Prat, Director of 4CB.
